Safety and efficacy of endoscopic vacuum therapy for the treatment of perforations and anastomotic leaks of the upper gastrointestinal tract.

Eficacia y seguridad de la terapia de vacío endoscópica para el tratamiento de perforaciones y dehiscencias anastomóticas del tracto digestivo superior.

Journal

Gastroenterologia y hepatologia
ISSN: 0210-5705
Titre abrégé: Gastroenterol Hepatol
Pays: Spain
ID NLM: 8406671

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 21 10 2019
revised: 19 01 2020
accepted: 23 01 2020
pubmed: 19 7 2020
medline: 25 2 2023
entrez: 19 7 2020
Statut: ppublish

Résumé

To evaluate the efficacy and safety of endoscopic vacuum therapy (EVT) in the management of perforations and anastomotic leaks of the upper gastrointestinal tract. This is a retrospective observational study which included patients who underwent EVT due to any upper gastrointestinal defect between April 2017 and February 2019 in three Spanish Hospitals. To this end, we used the only medical device approved to date for endoscopic use (Eso-SPONGEr; B. Braun Melsungen AG, Melsungen, Germany). 11 patients were referred for EVT of an anastomotic leak after esophagectomy (n=7), gastrectomy (n=2), esophageal perforation secondary to endoscopic Zenker's septomiotomy (n=1) and Boerhaave syndrome (n=1). The median size of the cavity was 8×3cm. The median delay between surgery and EVT was 7 days. The median of EVT duration was 28 days. The median number of sponges used was 7 and the mean period replacement was 3.7 days. In 10 cases (91%), the defect was successfully closed. In 9 cases (82%) clinical resolution of the septic condition was achieved. 5 patients presented some adverse event: 3 anastomotic strictures, 1 retropharyngeal pain and 1 case of new-onset pneumonia. The median hospital stay from the start of EVT was 45 days. 1 patient died owing to septic complications secondary to the anastomotic leak. EVT was successful in over 90% of perforations and anastomotic leaks of the upper gastrointestinal tract. Moreover, this is a safe therapy with only mild adverse events associated.

Identifiants

pubmed: 32680732
pii: S0210-5705(20)30227-2
doi: 10.1016/j.gastrohep.2020.01.019
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

431-438

Informations de copyright

Copyright © 2020 Elsevier España, S.L.U. All rights reserved.

Auteurs

O Sendino (O)

Unidad de Endoscopia, Servicio de Gastroenterología, ICMDiM, IDIBAPS, CIBEREHD, Hospital Clínic, Universitat de Barcelona, Barcelona, España. Electronic address: sendino@clinic.cat.

C Loras (C)

Servicio Digestivo, Hospital Universitari Mútua de Terrassa, Terrassa, España.

A Mata (A)

Unidad de Endoscopia, Departamento de Gastroenterología, Centro Médico Teknon, Barcelona, España.

D Momblán (D)

Servicio de Cirugía Gastrointestinal, ICMDiM, Hospital Clínic, Universitat de Barcelona, Barcelona, España.

X Andujar (X)

Servicio Digestivo, Hospital Universitari Mútua de Terrassa, Terrassa, España.

M Cruz (M)

Unidad de Endoscopia, Departamento de Gastroenterología, Centro Médico Teknon, Barcelona, España.

A Cárdenas (A)

Unidad de Endoscopia, Servicio de Gastroenterología, ICMDiM, IDIBAPS, CIBEREHD, Hospital Clínic, Universitat de Barcelona, Barcelona, España.

I Marquez (I)

Servicio Digestivo, Hospital Universitari Mútua de Terrassa, Terrassa, España.

H Uchima (H)

Unidad de Endoscopia, Departamento de Gastroenterología, Centro Médico Teknon, Barcelona, España.

H Cordova (H)

Unidad de Endoscopia, Servicio de Gastroenterología, ICMDiM, IDIBAPS, CIBEREHD, Hospital Clínic, Universitat de Barcelona, Barcelona, España.

A M de Lacy (AM)

Servicio de Cirugía Gastrointestinal, ICMDiM, IDIBAPS, CIBEREHD, AIS Channel, Hospital Clínic, Universitat de Barcelona, Barcelona, España.

J Espinós (J)

Servicio Digestivo, Hospital Universitari Mútua de Terrassa, Terrassa, España; Unidad de Endoscopia, Departamento de Gastroenterología, Centro Médico Teknon, Barcelona, España.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH